Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 203 Publications

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )
Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )
Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )
Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )
BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )
Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )
Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )
J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MmPURY51cW2rY4LvZolidCCDc4PhfS=>		NEf5cZIyQCCq	MkT5SG1UVw>?	NYfwengxSW62aYTyfZBidm:\|b33hcEBi[3Srdnn0fUB4cXSqIFXDOVAhd2ZiMD6wNFI2KM7:TR?=	NVf0XYdpOjR6MEW5OFY>
MCF7	NUTZRWNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDzRox3OC5yMT2xNFAh\|ryP	NYnQVYtjPDhiaB?=	MVjEUXNQ	NUDpSZZWUUN3ME2wMlc{KM7:TR?=	NVL2eVlTOjN6N{G5NFQ>
HCT116	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWewMlAyNTFyMDFOwG0>	M4n2NlQ5KGh?	MUjEUXNQ	MVvJR\|UxRTFwMU[g{txO	NV3TWoExOjN6N{G5NFQ>
U87MG	NXLwO\|AzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fP[FAvODFvMUCwJO69VQ>?	NYCxc3NOPDhiaB?=	MnLrSG1UVw>?	MUXJR\|UxRTFwM{Kg{txO	NILYdIczOzh5MUmwOC=>
HBC4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLQSVVWOC5yMT2xNFAh\|ryP	Mk[zOFghcA>?		MnrPUI9oKEeLNUC9MVgvPjFiTR?=	NYLLRWVUOjJ\|M{[yOFY>
BSY1	NIfGdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2K5OlAvODFvMUCwJO69VQ>?	M173U\|Q5KGh?		MoHxUI9oKEeLNUC9MVgvPDhiTR?=	MonNNlI{OzZ{NE[=
HBC5	M4HmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVT3cmd5OC5yMT2xNFAh\|ryP	NF7Dc2k1QCCq		MlnCUI9oKEeLNUC9MVcvQDdiTR?=	M4TLelIzOzN4MkS2
MCF7	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fUcFAvODFvMUCwJO69VQ>?	MXu0PEBp		M4TZfWxw\yCJSUWwQU05NjF4IF2=	Mn7xNlI{OzZ{NE[=
MDA-MB-231	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\QXGlKOC5yMT2xNFAh\|ryP	NGDvSWE1QCCq		NEXFd5hNd2diR1m1NF0uQC5yOTDN	NELk[VAzOjN\|NkK0Oi=>
U251	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnzNE4xOS1zMECg{txO	MU[0PEBp		NWDTR2U3VG:pIFfJOVA:NTdwNk[gUS=>	M1LHV\|IzOzN4MkS2
SF268	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofkNE4xOS1zMECg{txO	Moe2OFghcA>?		MYHMc4chT0l3ME2tO{46OiCP	M33VXVIzOzN4MkS2
SF295	NGP2OnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofRNE4xOS1zMECg{txO	MXe0PEBp		M4TUSmxw\yCJSUWwQU05NjNzIF2=	M1rFUVIzOzN4MkS2
SF539	NYnaXFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzHfIoxNjBzLUGwNEDPxE1?	NF;BV3M1QCCq		M{f5e2xw\yCJSUWwQU05NjV7IF2=	NVXSeJNtOjJ\|M{[yOFY>
SNB75	M4HWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTNNE4xOS1zMECg{txO	M2rme\|Q5KGh?		MoDBUI9oKEeLNUC9MVgvPThiTR?=	M4S3blIzOzN4MkS2
SNB78	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWwMlAyNTFyMDFOwG0>	M1fxOlQ5KGh?		NWfTcoVZVG:pIFfJOVA:NThwNkWgUS=>	NFHvcVczOjN\|NkK0Oi=>
HCC2998	NX2yZm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXQPIMxNjBzLUGwNEDPxE1?	MV:0PEBp		NYHzXZk2VG:pIFfJOVA:NThwMEWgUS=>	M2WxRVIzOzN4MkS2
KM12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVyxdnBvOC5yMT2xNFAh\|ryP	M3rE[\|Q5KGh?		MV3Mc4chT0l3ME2tO{42PCCP	MVqyNlM{PjJ2Nh?=
HT-29	NX6zWopsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXpNE4xOS1zMECg{txO	MmDaOFghcA>?		MV7Mc4chT0l3ME2tO{44PSCP	NHr5d4UzOjN\|NkK0Oi=>
HCT15	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLPVWcxNjBzLUGwNEDPxE1?	NXf6SY1CPDhiaB?=		NUi3XHJDVG:pIFfJOVA:NThwMEOgUS=>	M4Lr[\|IzOzN4MkS2
HCT116	M2DhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\TZlkxNjBzLUGwNEDPxE1?	MVK0PEBp		NWjxT3lZVG:pIFfJOVA:NTdwNkGgUS=>	M1jsUlIzOzN4MkS2
NCI-H23	NVXzPGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDJNE4xOS1zMECg{txO	M{DWblQ5KGh?		NHT5d3dNd2diR1m1NF0uPy54NDDN	NUTyTVl7OjJ\|M{[yOFY>
NCI-H226	NH3oW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTNO3hWOC5yMT2xNFAh\|ryP	M1S4d\|Q5KGh?		NFvWcYhNd2diR1m1NF0uQC52NDDN	NXTZbWZQOjJ\|M{[yOFY>
NCI-H522	NXnmV2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjw[IYxNjBzLUGwNEDPxE1?	Ml;COFghcA>?		MnLsUI9oKEeLNUC9MVgvPDViTR?=	NVjjTZNWOjJ\|M{[yOFY>
NCI-H438	NH\rXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHzNE4xOS1zMECg{txO	MmXlOFghcA>?		NWnxRYZKVG:pIFfJOVA:NThwMUGgUS=>	NGHVTVIzOjN\|NkK0Oi=>
A549	M1nvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXqNE4xOS1zMECg{txO	NV\EdpZIPDhiaB?=		NX72WHNjVG:pIFfJOVA:NThwMEegUS=>	M1nWdlIzOzN4MkS2
DMS273	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vRPFAvODFvMUCwJO69VQ>?	MoPnOFghcA>?		MVHMc4chT0l3ME2tO{45OCCP	NEjrZ\|IzOjN\|NkK0Oi=>
DMS114	NFnkWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGwMlAyNTFyMDFOwG0>	NFHpcVk1QCCq		M{jBbWxw\yCJSUWwQU05NjN7IF2=	Ml;uNlI{OzZ{NE[=
LOXIMVI	M4H5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjhNE4xOS1zMECg{txO	NFLQ[Yk1QCCq		M17vcGxw\yCJSUWwQU05NjZ4IF2=	NWHldnZzOjJ\|M{[yOFY>
OVCAR3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXywMlAyNTFyMDFOwG0>	M{HJSVQ5KGh?		NYLpPXgzVG:pIFfJOVA:NThwMUegUS=>	NXrpVIZkOjJ\|M{[yOFY>
OVCAR4	M1zjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTTNE4xOS1zMECg{txO	NHLmeo81QCCq		NIfp[IlNd2diR1m1NF0uQC53ODDN	NHvGRWMzOjN\|NkK0Oi=>
OVCAR5	NV7qPY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXve40xNjBzLUGwNEDPxE1?	NVmy[WppPDhiaB?=		NUn2VZlvVG:pIFfJOVA:NTdwNUegUS=>	MVSyNlM{PjJ2Nh?=
OVCAR8	NH3rVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuwMlAyNTFyMDFOwG0>	NWWxU3p5PDhiaB?=		NYGxV\|BwVG:pIFfJOVA:NTdwOESgUS=>	NFuxdJIzOjN\|NkK0Oi=>
SKOV3	MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXWwMlAyNTFyMDFOwG0>	MYq0PEBp		MWXMc4chT0l3ME2tPE41OSCP	MYqyNlM{PjJ2Nh?=
RXF631L	NX;6dpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCwMlAyNTFyMDFOwG0>	NVz3UY5XPDhiaB?=		NUmwc5BjVG:pIFfJOVA:NThwMkGgUS=>	M1zkdVIzOzN4MkS2
ACHN	M3LVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonDNE4xOS1zMECg{txO	NUT0e2ZWPDhiaB?=		NUnhcZc3VG:pIFfJOVA:NTdwOUWgUS=>	NXrxVXhTOjJ\|M{[yOFY>
St-4	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLIO5M6OC5yMT2xNFAh\|ryP	MX20PEBp		MVjMc4chT0l3ME2tO{41PyCP	Mnn5NlI{OzZ{NE[=
MKN1	NFG2eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUf5XlNjOC5yMT2xNFAh\|ryP	NW[2TXNbPDhiaB?=		NGnxbolNd2diR1m1NF0uQC52MTDN	NUjnS5Q2OjJ\|M{[yOFY>
MKN7	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXK4V3h[OC5yMT2xNFAh\|ryP	M2\INVQ5KGh?		NH3Zb4hNd2diR1m1NF0uPy54ODDN	MVyyNlM{PjJ2Nh?=
MKN28	M1Pjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUiwMlAyNTFyMDFOwG0>	NYPiXnJ6PDhiaB?=		Mo\TUI9oKEeLNUC9MVcvODdiTR?=	M4jMS\|IzOzN4MkS2
MKN45	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjQNE4xOS1zMECg{txO	MlTROFghcA>?		NEPpR3VNd2diR1m1NF0uQC5\|NDDN	MYiyNlM{PjJ2Nh?=
MKN74	NI\MeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;JNE4xOS1zMECg{txO	NHz2PG81QCCq		MlfiUI9oKEeLNUC9MVcvPDJiTR?=	Mn3ONlI{OzZ{NE[=
DU145	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWKwMlAyNTFyMDFOwG0>	NFG3Opk1QCCq		NXHDW5BWVG:pIFfJOVA:NThwMU[gUS=>	MUKyNlM{PjJ2Nh?=
PC3	NWfNd2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXZNE4xOS1zMECg{txO	MVW0PEBp		NIruWmhNd2diR1m1NF0uQC54NjDN	NEnNPFIzOjN\|NkK0Oi=>
Trypanosoma brucei brucei	NES1[25HfW6ldHnvckBCe3OjeR?=	MVyyNFAhdk1?	NWPES4VVOTJiaB?=	NIWwRppFVVOR	MX7E[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	Mm\5NlQ5ODV7NE[=
Trypanosoma brucei brucei	M1zsPWZ2dmO2aX;uJGF{e2G7		NXThW4lMOThiaB?=	NInqWHVFVVOR	MnzLTY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	Mm\lNlQ5ODV7NE[=
Trypanosoma brucei brucei	NF\nb2JHfW6ldHnvckBCe3OjeR?=	M1jnPFIxOCCwTR?=	M4PQR\|EzKGh?	M2PMVmROW09?	MWnF[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>	NIfDc2MzPDhyNUm0Oi=>
Trypanosoma brucei brucei	NVvGVIR[TnWwY4Tpc44hSXO\|YYm=	MnXQNlAxKG6P	MnL1NVIhcA>?	M{\DcGROW09?	NXrq[G53TW[oZXP0JI9vKHCqb4PwbIF1cWS7bHPoc4xqdmVibHX2[Yw>	NXG5WlFoOjR6MEW5OFY>
UM-UC-3	M2DDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTNzNTDwUS=>	MoX5V2FPT0WU
SBC-1	NY\lSYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTd2MjDwUS=>	NWSzVGlpW0GQR1XS
MKN1	M3XPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\zTWM2OD1{Lkigcm0>	M2C0cnNCVkeHUh?=
NCI-H720	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTNwNUegcm0>	MoTOV2FPT0WU
BFTC-909	NFLobXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTNwN{Ggcm0>	NUfOTXhsW0GQR1XS
BPH-1	M2Pjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfYZpZKSzVyPUSuO\|Yhdk1?	M4HlVXNCVkeHUh?=
PC-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfqTWM2OD13LkC5JI5O	NUO0bIhbW0GQR1XS
AN3-CA	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfNVm5KSzVyPUWuOVYhdk1?	MkTWV2FPT0WU
HN	NYHDNoZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPsTWM2OD13Lkm2JI5O	NHu4W4VUSU6JRWK=
HCC2218	M{DzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzZN29KSzVyPU[uOlEhdk1?	NXS5fnFHW0GQR1XS
KP-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYD6dJd2UUN3ME23JI5O	M3SzdHNCVkeHUh?=
LU-139	NFL2OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn4O4VxUUN3ME23Mlc4KG6P	MnTsV2FPT0WU
ETK-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zHRWlEPTB;Nz64PEBvVQ>?	M4HZR3NCVkeHUh?=
Ramos-2G6-4C10	M2rFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\GcmlEPTB;OD60PUBvVQ>?	MoHYV2FPT0WU
MHH-PREB-1	NUXy[Hc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTlwMUKgcm0>	MkPnV2FPT0WU
DU-4475	NHjUZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTlwNESgcm0>	NWPrUHJuW0GQR1XS
NCI-H1666	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTlwN{Ggcm0>	MojmV2FPT0WU
CAMA-1	M3rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXGW2lKSzVyPUmuPEBvVQ>?	NHTCPYZUSU6JRWK=
TYK-nu	M2TpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;nTm9KSzVyPUmuPVQhdk1?	NVPaVWdqW0GQR1XS
MFE-280	NWTnWoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTlwOUmgcm0>	NX3qWWVTW0GQR1XS
A549	MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPjO\|NXUUN3ME2xNE4yPCCwTR?=	M{\iTHNCVkeHUh?=
769-P	M1KwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jvcWlEPTB;MUCuOFQhdk1?	NFvLXnNUSU6JRWK=
L-363	M3nCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jaSWlEPTB;MUCuOlkhdk1?	NFPONGVUSU6JRWK=
ES8	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjxTWM2OD1zMD65JI5O	M3fkXXNCVkeHUh?=
PA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTFzLkiyJI5O	NWHJRVV7W0GQR1XS
Mewo	M4DEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInSVFZKSzVyPUGxMlk6KG6P	M2TFSXNCVkeHUh?=
HSC-3	MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF{LkKxJI5O	MYjTRW5ITVJ?
H4	M2[4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHTc5BKSzVyPUGyMlY4KG6P	M2G0O3NCVkeHUh?=
BB65-RCC	NUO5ToxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTF{LkeyJI5O	MVTTRW5ITVJ?
NCI-H1793	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr4[ZdKSzVyPUGyMlgzKG6P	MYDTRW5ITVJ?
KARPAS-45	NHTPTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LJSmlEPTB;MUOuOVEhdk1?	MUTTRW5ITVJ?
GCT	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfp[WZ3UUN3ME2xN{43QCCwTR?=	MUTTRW5ITVJ?
EoL-1	NUjkVmoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHVV2NKSzVyPUGzMlk{KG6P	NHqyNYhUSU6JRWK=
LB2241-RCC	NYfBNYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF2LkCxJI5O	MnO1V2FPT0WU
ES5	M3L1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TTSWlEPTB;MUSuO\|Qhdk1?	NFTTWJhUSU6JRWK=
LOXIMVI	M13E[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jHRWlEPTB;MUSuPVkhdk1?	NEGxWYFUSU6JRWK=
COR-L105	NFP0c2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTF3LkC0JI5O	NH7XXoVUSU6JRWK=
P12-ICHIKAWA	M2XuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PHbWlEPTB;MUWuNUBvVQ>?	MVjTRW5ITVJ?
CHL-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[3UWQ4UUN3ME2xOU41PSCwTR?=	MX;TRW5ITVJ?
VMRC-RCZ	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnvNHhKSzVyPUG1MlY{KG6P	MkK1V2FPT0WU
HH	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTF3Lkegcm0>	NYLWXFRCW0GQR1XS
NUGC-3	M3rKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFG1TY9KSzVyPUG2MlM1KG6P	MlPFV2FPT0WU
EGI-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF4LkSzJI5O	M4XtVXNCVkeHUh?=
OS-RC-2	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXHVZNkUUN3ME2xOk41PyCwTR?=	MUXTRW5ITVJ?
MOLT-16	M4fsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHkeWdsUUN3ME2xO{4yPSCwTR?=	NULzcIxmW0GQR1XS
NCI-H209	M3:2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3RdnBKSzVyPUG3MlI6KG6P	M2flU3NCVkeHUh?=
697	NV\NWpZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zCZmlEPTB;MUeuOFMhdk1?	MkSwV2FPT0WU
D-56MG	NVjxXlVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfJVFlKSzVyPUG3MlY6KG6P	NXXodGlyW0GQR1XS
VA-ES-BJ	NUD4cnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fmVWlEPTB;MUeuPFMhdk1?	NHe5cGhUSU6JRWK=
EW-16	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXT1V3FtUUN3ME2xPE4xPCCwTR?=	MojmV2FPT0WU
HGC-27	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVG4fnQyUUN3ME2xPE4xPiCwTR?=	MXrTRW5ITVJ?
ES7	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP1TWM2OD1zOD6wPUBvVQ>?	NGDQdZFUSU6JRWK=
HuH-7	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr4[pNKSzVyPUG4MlQhdk1?	MlvKV2FPT0WU
BCPAP	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPN[\|J2UUN3ME2xPE43PSCwTR?=	NVvxS5N3W0GQR1XS
SW1710	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXZOFJKSzVyPUG4MlczKG6P	MorTV2FPT0WU
IST-MEL1	NFr2XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW5fGtKSzVyPUG4Mlc4KG6P	M2DxWXNCVkeHUh?=
SF295	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTF6LkmzJI5O	MoW5V2FPT0WU
RPMI-7951	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLNT45oUUN3ME2xPU4zQCCwTR?=	NWDnU45FW0GQR1XS
SF126	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLueld6UUN3ME2xPU41OSCwTR?=	NFHvPXRUSU6JRWK=
GAMG	NVPJTYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXeydll3UUN3ME2xPU41QCCwTR?=	M321PHNCVkeHUh?=
KNS-81-FD	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vmW2lEPTB;MUmuOVQhdk1?	MXvTRW5ITVJ?
RT-112	NHO5UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Tj[2lEPTB;MUmuOlYhdk1?	NWjZNpJQW0GQR1XS
DEL	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfqTWM2OD1{MD60PUBvVQ>?	NXixNFlXW0GQR1XS
CGTH-W-1	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTvTWM2OD1{MD62N{BvVQ>?	NFr0PZRUSU6JRWK=
HOS	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJzLkC2JI5O	Mnr3V2FPT0WU
ES4	NV35elFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j2SWlEPTB;MkGuNFghdk1?	MYLTRW5ITVJ?
RXF393	NILx[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJzLkS1JI5O	M3XaT3NCVkeHUh?=
NCI-H2030	NInGT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJzLkWyJI5O	NH7IZYZUSU6JRWK=
YH-13	NF7G[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnS[WpbUUN3ME2yNU45QCCwTR?=	MYHTRW5ITVJ?
HT-1080	M3zWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojJTWM2OD1{MT65N{BvVQ>?	NF;TWYFUSU6JRWK=
NCI-SNU-1	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTucYJKSzVyPUKxMlk2KG6P	NXy1N2E1W0GQR1XS
G-402	M{\MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTJ{LkG2JI5O	NUHsTGJEW0GQR1XS
786-0	NUTyU4pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljKTWM2OD1{Mj6yPUBvVQ>?	MlrmV2FPT0WU
ME-180	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vqNGlEPTB;MkKuOFMhdk1?	NGHreY5USU6JRWK=
NB69	MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzETWM2OD1{Mj61N{BvVQ>?	M3jhVHNCVkeHUh?=
J-RT3-T3-5	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLvcmJ4UUN3ME2yNk46PiCwTR?=	NFLjV2tUSU6JRWK=
TGBC1TKB	NH62[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXi4[4JTUUN3ME2yN{4xPSCwTR?=	NH\DS4VUSU6JRWK=
SW780	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTJ\|LkGzJI5O	M371SHNCVkeHUh?=
MG-63	M1vWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnvTWM2OD1{Mz60OUBvVQ>?	Mn;iV2FPT0WU
BV-173	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1i2NmlEPTB;MkOuPFchdk1?	MV\TRW5ITVJ?
CAL-51	NX;OcmpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTJ\|Lki5JI5O	NFX2Z4JUSU6JRWK=
A375	NWjFXmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnsTWM2OD1{Mz65N{BvVQ>?	M13JOnNCVkeHUh?=
MEL-HO	M3\zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LnWGlEPTB;MkSuNFQhdk1?	MlvXV2FPT0WU
EFO-27	NWjlO257T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDvNZlpUUN3ME2yOE4{OyCwTR?=	M3\qdXNCVkeHUh?=
Hs-578-T	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTXTWM2OD1{ND61PEBvVQ>?	MX;TRW5ITVJ?
NBsusSR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJ2Lk[gcm0>	MnnPV2FPT0WU
CTB-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTBflNSUUN3ME2yOE43PyCwTR?=	M{j1XXNCVkeHUh?=
FTC-133	M3PPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF:xR2tKSzVyPUK1MlEhdk1?	M1PS[XNCVkeHUh?=
MOLT-4	NVrmdo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ3LkGyJI5O	NV7VSoI2W0GQR1XS
HO-1-N-1	NEX5b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnnTWM2OD1{NT6xOUBvVQ>?	MoPMV2FPT0WU
ES3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TMXGlEPTB;MkWuNlIhdk1?	NVzCfFlnW0GQR1XS
TI-73	NVzyNXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKzTXlFUUN3ME2yOU4zQCCwTR?=	MkDwV2FPT0WU
MPP-89	M4XFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHu1XZJKSzVyPUK1MlMzKG6P	M1n1VXNCVkeHUh?=
KYSE-150	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13IVGlEPTB;MkWuPFkhdk1?	MVHTRW5ITVJ?
LXF-289	NXPs[JRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUm3bWlHUUN3ME2yOk4xPCCwTR?=	M4TZOXNCVkeHUh?=
SK-LU-1	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XYWmlEPTB;Mk[uNVchdk1?	NEPYXHRUSU6JRWK=
HOP-92	M1nybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonOTWM2OD1{Nj60PEBvVQ>?	MoqzV2FPT0WU
HuO9	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1e4dGlEPTB;Mk[uO\|Yhdk1?	NV:xPGlvW0GQR1XS
SW962	M4HDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHr4V4xKSzVyPUK2Mlc3KG6P	MkHtV2FPT0WU
RS4-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXmco1UUUN3ME2yOk46OSCwTR?=	NUfiXJlIW0GQR1XS
NCI-H292	M3zRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLMTWM2OD1{NzDuUS=>	NVfMdmluW0GQR1XS
DB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX34enRwUUN3ME2yO{4{PiCwTR?=	NELSNHhUSU6JRWK=
SW1088	NW\mRW1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVT1Xnk4UUN3ME2yPE4zQSCwTR?=	NHXW[otUSU6JRWK=
A204	NIP6d25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLQfGNxUUN3ME2yPE41PyCwTR?=	M{Xw[HNCVkeHUh?=
A3-KAW	NYjMS3hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJ6Lk[0JI5O	MYPTRW5ITVJ?
MV-4-11	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vl[GlEPTB;MkiuO{BvVQ>?	M3XjbnNCVkeHUh?=
ES1	NF;2UnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n4eWlEPTB;MkiuPFQhdk1?	MVnTRW5ITVJ?
ONS-76	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJ7LkC1JI5O	MWLTRW5ITVJ?
D-263MG	NGG3SGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjPTFFjUUN3ME2yPU4{PSCwTR?=	M3vBVnNCVkeHUh?=
U-2-OS	NXTscGo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrQUFJiUUN3ME2yPU42KG6P	MXHTRW5ITVJ?
T98G	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTUUm9nUUN3ME2yPU45QCCwTR?=	MVnTRW5ITVJ?
GI-ME-N	NHHSZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfhTWM2OD1{OT65NUBvVQ>?	NVq5O5hmW0GQR1XS
BHT-101	M3K5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTNyLkC1JI5O	MVnTRW5ITVJ?
NOS-1	M1zmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rBUGlEPTB;M{CuNVIhdk1?	M{HRWnNCVkeHUh?=
AsPC-1	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTNyLkKgcm0>	NIC1VZVUSU6JRWK=
QIMR-WIL	M1rSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoOzTWM2OD1\|MD62JI5O	M2izfnNCVkeHUh?=
JVM-3	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTNyLkizJI5O	NV\BfmZ3W0GQR1XS
KU-19-19	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3H4SWlEPTB;M{GuNVMhdk1?	M2G2Z3NCVkeHUh?=
OVCAR-8	M1PJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7STWM2OD1\|MT6yOkBvVQ>?	NIjqdIpUSU6JRWK=
BEN	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHnbZRKSzVyPUOxMlY{KG6P	M1vGZnNCVkeHUh?=
BE-13	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfzcoQ4UUN3ME2zNU45OiCwTR?=	NI\CWHRUSU6JRWK=
EW-18	NEixRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITFNJpKSzVyPUOxMlg3KG6P	NGDse5ZUSU6JRWK=
ECC10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH64RZNKSzVyPUOxMlk2KG6P	MkO4V2FPT0WU
CTV-1	NIPmXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTN{LkiyJI5O	MnTSV2FPT0WU
COLO-800	NGHDUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnR[\|BwUUN3ME2zNk46OiCwTR?=	MXnTRW5ITVJ?
A2058	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm3fXJSUUN3ME2zN{4zPSCwTR?=	NFfaUGxUSU6JRWK=
VM-CUB-1	NVnITlRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUi3Uo5{UUN3ME2zN{41OyCwTR?=	MXTTRW5ITVJ?
Ca9-22	NYXYfoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jRNmlEPTB;M{OuOVUhdk1?	NGfXWpVUSU6JRWK=
COLO-684	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEOyTHhKSzVyPUOzMlU5KG6P	MYDTRW5ITVJ?
RPMI-8226	NHLMNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvLTWM2OD1\|Mz64NkBvVQ>?	MWfTRW5ITVJ?
SK-NEP-1	NWW0O2t1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFuwc\|BKSzVyPUO0MlE2KG6P	MlXGV2FPT0WU
Becker	NVPoR4pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\pN\|dKSzVyPUO0MlIyKG6P	NI\Tb3RUSU6JRWK=
NCI-H28	M1\pTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1e0T2lEPTB;M{SuOFQhdk1?	NInrSZNUSU6JRWK=
CAL-120	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfIbm1KSzVyPUO0MlczKG6P	NH;iR4lUSU6JRWK=
MDA-MB-157	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nTSWlEPTB;M{WuOFEhdk1?	NH;kboVUSU6JRWK=
OVCAR-5	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHE[4dKSzVyPUO1MlQ4KG6P	MUDTRW5ITVJ?
LAMA-84	NHj6NlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3qTWM2OD1\|NT64O{BvVQ>?	M{npTnNCVkeHUh?=
CAKI-1	NVP5W\|hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETYcYdKSzVyPUO2MlQ{KG6P	NEj3SIxUSU6JRWK=
Daoy	NHPqR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTN4Lkegcm0>	Mlu0V2FPT0WU
CAL-62	NHOwbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2CxOWlEPTB;M{[uPFYhdk1?	MWjTRW5ITVJ?
8-MG-BA	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnVUXB5UUN3ME2zO{4zPSCwTR?=	MnPsV2FPT0WU
8505C	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NESybldKSzVyPUO3MlUyKG6P	NUG5e21[W0GQR1XS
LNCaP-Clone-FGC	NFv4d5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PrS2lEPTB;M{euOVkhdk1?	M1XZT3NCVkeHUh?=
CAL-39	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTN5Lkmgcm0>	Ml7MV2FPT0WU
MN-60	NUXtVppYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnHUFVqUUN3ME2zO{46PiCwTR?=	MkDLV2FPT0WU
RKO	NVH1cZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\6R2lEPTB;M{iuN\|Mhdk1?	MX3TRW5ITVJ?
U251	M3;Oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLmPGZKSzVyPUO4MlQ{KG6P	MUnTRW5ITVJ?
SJSA-1	NEPyXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTN6LkW0JI5O	NIHZcYxUSU6JRWK=
CAL-12T	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTN6Lk[gcm0>	M2T4T3NCVkeHUh?=
HCC1419	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTN6LkexJI5O	MWrTRW5ITVJ?
CO-314	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHEVmNKSzVyPUO4Mlc1KG6P	NEjqfGxUSU6JRWK=
LB1047-RCC	NWXScmRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN6LkixJI5O	MWHTRW5ITVJ?
A101D	Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTN6Lkm3JI5O	NGn3eG9USU6JRWK=
MDA-MB-175-VII	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXLOJdKSzVyPUO5MlUyKG6P	MojrV2FPT0WU
MZ2-MEL	M2H1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33vemlEPTB;M{muOlYhdk1?	NY\LfItyW0GQR1XS
NB5	M3T4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jnNmlEPTB;NECuOlQhdk1?	Mlv1V2FPT0WU
G-401	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTRyLkiyJI5O	MUDTRW5ITVJ?
HT	NEm5VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfBTWM2OD12MT6wNkBvVQ>?	Mkm0V2FPT0WU
8305C	NFziUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHFOoRKSzVyPUSxMlg4KG6P	NXPHcWhkW0GQR1XS
BHY	M2\wRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTR{LkeyJI5O	NIfUcFFUSU6JRWK=
NTERA-S-cl-D1	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTR\|IH7N	M12xN3NCVkeHUh?=
T-24	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljqTWM2OD12Mz64N{BvVQ>?	NHTOdFBUSU6JRWK=
EPLC-272H	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXwTVhrUUN3ME20OE4{QSCwTR?=	MoLCV2FPT0WU
PSN1	NI\IXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC0d45KSzVyPUS0MlQhdk1?	NETkclBUSU6JRWK=
NCI-H2452	NXvPboN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTxVYtKSzVyPUS0MlU5KG6P	NFi1TZpUSU6JRWK=
KS-1	M124dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYmxRpBSUUN3ME20OE43PiCwTR?=	NX7HUo5UW0GQR1XS
HD-MY-Z	NFPLVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\CZpJKSzVyPUS0MlkzKG6P	Mn;jV2FPT0WU
KNS-62	NH3QV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPPTWM2OD12NT6zPEBvVQ>?	NUDoZpd2W0GQR1XS
NOMO-1	NHK0Z\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnhTWM2OD12NT64O{BvVQ>?	NYLIVlg1W0GQR1XS
SK-HEP-1	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\3NlJMUUN3ME20Ok4xPCCwTR?=	Ml7KV2FPT0WU
IGR-1	NGPnZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLPTWM2OD12Nj6xN{BvVQ>?	M2rDW3NCVkeHUh?=
KYSE-180	NV\KRXkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[wRnFKSzVyPUS2MlE4KG6P	NV7s[YlFW0GQR1XS
EW-22	NYTFeYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGq4ZlZKSzVyPUS2MlIhdk1?	MlLYV2FPT0WU
NCI-H1355	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnoUVZoUUN3ME20Ok4{PCCwTR?=	MULTRW5ITVJ?
DOHH-2	NXPZW3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTR4LkO3JI5O	NYfvUJVIW0GQR1XS
A4-Fuk	MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS1dXkyUUN3ME20Ok42OiCwTR?=	NYXQcI1LW0GQR1XS
PC-14	NUn0R5NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7kUndKSzVyPUS2MlU4KG6P	MnXYV2FPT0WU
TE-5	NF7nNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\BenVKSzVyPUS2Mlg1KG6P	NF3pTmlUSU6JRWK=
LB996-RCC	M3jnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH5bnZJUUN3ME20O{4yQSCwTR?=	M3\6XnNCVkeHUh?=
NCI-H1623	NHT0WZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTR5Lke2JI5O	MorDV2FPT0WU
NCI-H1155	NY\3R2FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[0VWlEPTB;NEiuN\|Ihdk1?	MkHPV2FPT0WU
LoVo	NXf3bm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPPTWM2OD12OD60JI5O	MorHV2FPT0WU
MCF7	NUPwfZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHkTWM2OD12OD61PEBvVQ>?	NVrqb3lJW0GQR1XS
AGS	M{ixR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXhXVlYUUN3ME20PE44PyCwTR?=	M3vVd3NCVkeHUh?=
PFSK-1	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\0TWM2OD12OT6wOkBvVQ>?	MlLNV2FPT0WU
22RV1	NUG4T\|VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37SPGlEPTB;NEmuNFkhdk1?	NWPaXVNxW0GQR1XS
COR-L23	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmO1TWM2OD12OT6xOkBvVQ>?	NIDkb2VUSU6JRWK=
D-283MED	NX;Uc2F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrGU3BKSzVyPUS5MlYyKG6P	NFvme4lUSU6JRWK=
SW982	M1r6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDaTWM2OD12OT65NUBvVQ>?	MX\TRW5ITVJ?
SW620	MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkiyTWM2OD13MD6zOkBvVQ>?	MmruV2FPT0WU
KYSE-140	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfPZo9KSzVyPUWwMlU2KG6P	MYjTRW5ITVJ?
GCIY	NGDZW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPCfHhVUUN3ME21NE43PyCwTR?=	NVOxfG1{W0GQR1XS
MHH-ESS-1	NWrReIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLSWWd7UUN3ME21NU46PSCwTR?=	NEK1PGVUSU6JRWK=
D-423MG	NHv0TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTV{LkC4JI5O	MnTDV2FPT0WU
SF539	M1L5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHGfnhUUUN3ME21Nk4{PSCwTR?=	MWHTRW5ITVJ?
RPMI-2650	NILhNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTV{Lk[5JI5O	MYnTRW5ITVJ?
GR-ST	M3HYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPiTmNKSzVyPUWyMlg4KG6P	Ml;DV2FPT0WU
YKG-1	NFe0cVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTV\|IH7N	M1\vW3NCVkeHUh?=
SK-MES-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYX1S3VzUUN3ME21N{4zPiCwTR?=	NWe3TWh5W0GQR1XS
HLE	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHThRYZKSzVyPUWzMlQ4KG6P	M4rBTXNCVkeHUh?=
RVH-421	M2nMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjjTm1mUUN3ME21N{43PyCwTR?=	NYf2TZlzW0GQR1XS
C32	MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTV\|LkizJI5O	MWDTRW5ITVJ?
GB-1	M2XJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIiyXGVKSzVyPUW0MlIhdk1?	M2PtN3NCVkeHUh?=
SNB75	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nFdWlEPTB;NUSuNlYhdk1?	Ml3zV2FPT0WU
EM-2	M2rjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDkTWM2OD13ND60JI5O	NIDMUpFUSU6JRWK=
RH-1	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTV2Lkegcm0>	MXvTRW5ITVJ?
NKM-1	NV\Q[nNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvSTWM2OD13ND64NUBvVQ>?	M3;jdHNCVkeHUh?=
NCI-H2405	M1PFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfoTWM2OD13ND64PEBvVQ>?	M1:zc3NCVkeHUh?=
KYSE-450	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\mVWlEPTB;NUWuNVYhdk1?	M3nWV3NCVkeHUh?=
A704	M3fUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Tse2lEPTB;NUWuOVkhdk1?	M{\TcXNCVkeHUh?=
HAL-01	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvx[3ZDUUN3ME21OU45OyCwTR?=	M2nOUXNCVkeHUh?=
TE-11	NEHUeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlz2TWM2OD13NT65PUBvVQ>?	MojCV2FPT0WU
DOK	M3rkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTV4LkCyJI5O	NV3zT3p{W0GQR1XS
KY821	NXfDZWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;nTWM2OD13Nj6yJI5O	NHS3[ZBUSU6JRWK=
KGN	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW1TWM2OD13Nj6zNkBvVQ>?	NYLVbJVwW0GQR1XS
MC116	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37MTGlEPTB;NUeuPEBvVQ>?	NXHzfFNjW0GQR1XS
PANC-08-13	NHHYbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHl[4dKSzVyPUW4MlAyKG6P	M37xSXNCVkeHUh?=
KE-37	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzqTWM2OD13OD63O{BvVQ>?	NYXHW4lkW0GQR1XS
KYSE-410	NYXDOpNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17ZS2lEPTB;NUmuOFchdk1?	MlfPV2FPT0WU
RO82-W-1	M2DlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTV7Lkmgcm0>	NGjvO2FUSU6JRWK=
M14	NYfzfo55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFniW45KSzVyPU[wMlA1KG6P	M4i2[XNCVkeHUh?=
GI-1	MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTZyLkOgcm0>	MVXTRW5ITVJ?
ML-2	NEGwcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTZyLk[yJI5O	NV6yWlE5W0GQR1XS
BFTC-905	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTZyLk[1JI5O	NXX2cJM4W0GQR1XS
DMS-273	MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XrNmlEPTB;NkCuPFchdk1?	M1;2XnNCVkeHUh?=
MDA-MB-361	MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP2fJVCUUN3ME22NUBvVQ>?	MXPTRW5ITVJ?
MSTO-211H	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTZ\|LkWxJI5O	NETDTGJUSU6JRWK=
MEG-01	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\kUZVRUUN3ME22N{42OiCwTR?=	MlzqV2FPT0WU
M059J	MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELld2FKSzVyPU[zMlU5KG6P	Ml;WV2FPT0WU
LN-405	M3\xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXrcZdKSzVyPU[zMlg2KG6P	MnHEV2FPT0WU
NCI-H1581	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnPfHlSUUN3ME22OE4xOyCwTR?=	NYXIOXcyW0GQR1XS
TCCSUP	NFruO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmf5TWM2OD14ND61N{BvVQ>?	NU\ld41UW0GQR1XS
SW872	M4e0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvDTWM2OD14ND61O{BvVQ>?	NX:yOXZPW0GQR1XS
KYSE-510	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWWz[mV6UUN3ME22OU44PSCwTR?=	MWDTRW5ITVJ?
NCI-H1792	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XROGlEPTB;Nk[uNVUhdk1?	MlrKV2FPT0WU
SW13	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPQN3ZKSzVyPU[2MlUhdk1?	M1;NWnNCVkeHUh?=
TE-8	M3T4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XsT2lEPTB;Nk[uOVIhdk1?	MWPTRW5ITVJ?
SCH	NXjsUHgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1H3W2lEPTB;NkeuNUBvVQ>?	M3nzTHNCVkeHUh?=
NEC8	NGPHWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTN[IxKSzVyPU[3MlI1KG6P	M{XUWnNCVkeHUh?=
HuO-3N1	NXrJ[nJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkH4TWM2OD14Nz6zNUBvVQ>?	MWjTRW5ITVJ?
EFM-19	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHMTWM2OD14Nz61JI5O	MX\TRW5ITVJ?
HEC-1	NEPNUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zyUGlEPTB;NkeuOVIhdk1?	MoHEV2FPT0WU
T47D	NXuyWZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHMTWM2OD14Nz64O{BvVQ>?	MkTmV2FPT0WU
SNU-423	NE\WVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTZ5Lkm4JI5O	NXK1eHFXW0GQR1XS
WM-115	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTYWGlKSzVyPU[4MlE1KG6P	NUfUb3FzW0GQR1XS
CaR-1	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HsRmlEPTB;NkiuNlUhdk1?	MmTsV2FPT0WU
KU812	NYnld3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\sbWlEPTB;NkiuOlkhdk1?	MV3TRW5ITVJ?
AM-38	NWfjWXZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInMV5RKSzVyPU[5MlMyKG6P	MVLTRW5ITVJ?
KOSC-2	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfhTWM2OD14OT65O{BvVQ>?	NFfFWI1USU6JRWK=
MC-IXC	M1nRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTdyLkC4JI5O	NGe3c4FUSU6JRWK=
SCC-4	M2DYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInFR5ZKSzVyPUexMlM5KG6P	MY\TRW5ITVJ?
Calu-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PYfGlEPTB;N{GuPVghdk1?	Mke2V2FPT0WU
RPMI-8866	M3TZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzaTWM2OD15Mj64NkBvVQ>?	NXvkcI4xW0GQR1XS
OVCAR-4	M3Swb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHTU3VvUUN3ME23N{4{PiCwTR?=	NGj1VYdUSU6JRWK=
OAW-42	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPMTWM2OD15Mz6zPUBvVQ>?	NFPaZXNUSU6JRWK=
ATN-1	M4Xtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWmwfnhCUUN3ME23N{45PyCwTR?=	MXPTRW5ITVJ?
CHP-212	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrGbmhKSzVyPUe0Mlk2KG6P	MVvTRW5ITVJ?
C2BBe1	MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTd3LkCzJI5O	MYXTRW5ITVJ?
A498	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrDeoJQUUN3ME23OU4yPSCwTR?=	Mo\IV2FPT0WU
SH-4	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW4NHdCUUN3ME23OU4zOSCwTR?=	M2e0RnNCVkeHUh?=
SNU-449	M3zL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLFTWM2OD15NT63PUBvVQ>?	MXjTRW5ITVJ?
RD	NX3iTIZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;JTWM2OD15NT64OkBvVQ>?	M1S2V3NCVkeHUh?=
PANC-03-27	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn0boJKSzVyPUe2MlI2KG6P	M{O3SXNCVkeHUh?=
S-117	M3i1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTkTWM2OD15Nj6yO{BvVQ>?	M4r6S3NCVkeHUh?=
SK-MEL-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrG[2dKSzVyPUe2Mlc2KG6P	MULTRW5ITVJ?
LK-2	NH3Vc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTd5LkC1JI5O	M1fHOXNCVkeHUh?=
CP50-MEL-B	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTd5LkSgcm0>	NHfESmNUSU6JRWK=
647-V	M17HRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorYTWM2OD15OD6wO{BvVQ>?	MXHTRW5ITVJ?
LU-134-A	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LjPWlEPTB;N{muNFMhdk1?	MlL1V2FPT0WU
5637	M2LZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfsPFF{UUN3ME23PU4zOyCwTR?=	MnvZV2FPT0WU
NCI-H1437	MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfnXHVNUUN3ME24NE42KG6P	NWPyNW93W0GQR1XS
NCI-H460	M1XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHO2d\|VKSzVyPUixMlI{KG6P	NV\LSJVwW0GQR1XS
BxPC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4flfWlEPTB;OEGuOFYhdk1?	NFnFWIVUSU6JRWK=
CAN	NVLTbVhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\iPVg6UUN3ME24NU45PCCwTR?=	NHrlOnZUSU6JRWK=
KINGS-1	NHXYZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDKellqUUN3ME24Nk4{OiCwTR?=	MWrTRW5ITVJ?
OCUB-M	NVLqUGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TLfGlEPTB;OEKuOFEhdk1?	NYn5S2NQW0GQR1XS
KALS-1	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTh{LkW0JI5O	M3zjTHNCVkeHUh?=
OCI-AML2	M1PwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkGxTWM2OD16Mj62NUBvVQ>?	MW\TRW5ITVJ?
A253	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnycXBKSzVyPUiyMlY2KG6P	NGDPU2VUSU6JRWK=
LCLC-97TM1	NUnDXlVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\DToNKSzVyPUiyMlg3KG6P	M4DsV3NCVkeHUh?=
NCI-H520	NFXKV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWj3emdKUUN3ME24N{4xPiCwTR?=	NGDEdZFUSU6JRWK=
P30-OHK	Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTh\|LkWgcm0>	NUTxU5dHW0GQR1XS
SBC-5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXuTlRKSzVyPUizMlUzKG6P	NEXDcIFUSU6JRWK=
HCE-T	NVHyPWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPre2ZKSzVyPUizMlc1KG6P	NFm0ZmVUSU6JRWK=
JEG-3	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTh2LkGgcm0>	NGrOfFlUSU6JRWK=
KG-1	NWG2ZplxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTITWM2OD16ND6yOEBvVQ>?	NYTUeJpMW0GQR1XS
MIA-PaCa-2	Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml[1TWM2OD16ND61OEBvVQ>?	MXvTRW5ITVJ?
CAL-33	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTuTWM2OD16NT6wPEBvVQ>?	M2jhWnNCVkeHUh?=
639-V	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXG5OmRVUUN3ME24OU41OiCwTR?=	NUfKNWp3W0GQR1XS
NCI-H1048	NIHhVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTh4LkOxJI5O	Mon1V2FPT0WU
NCI-H1573	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnNb3gyUUN3ME24O{41QCCwTR?=	MYHTRW5ITVJ?
NCI-H2228	NYXuTWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLwSYNPUUN3ME24PE4zPiCwTR?=	NVzKXI1JW0GQR1XS
NB14	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLkTWM2OD16OD6zJI5O	MXrTRW5ITVJ?
SCC-25	NWDqS2hET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPCTWM2OD16OT64NkBvVQ>?	NUPJflRpW0GQR1XS
A431	MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGzWZdyUUN3ME24PU46PyCwTR?=	M3TJdnNCVkeHUh?=
SN12C	NETVdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nRUmlEPTB;OUCuOlIhdk1?	NEXY[5BUSU6JRWK=
HuCCT1	NFrMS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTlyLke2JI5O	M4i0PHNCVkeHUh?=
LS-123	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTl{LkG4JI5O	NWewU\|ZzW0GQR1XS
CAL-85-1	NVH1[mJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W5SWlEPTB;OUKuOFghdk1?	NF\QdYhUSU6JRWK=
ES6	NVO3elAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLOUmhKSzVyPUmyMlg{KG6P	NYnGblJTW0GQR1XS
NCI-H650	M2rDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{[xUGlEPTB;OUSuNFkhdk1?	NXztT2JOW0GQR1XS
NCI-H446	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTl3LkGyJI5O	MojhV2FPT0WU
EW-13	Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnQSnJzUUN3ME25OU44PSCwTR?=	NX7GNXM5W0GQR1XS
HSC-2	NG\3dHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jjemlEPTB;OUWuPFkhdk1?	MkDtV2FPT0WU
U031	NFjrUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jrVGlEPTB;OU[uO\|Mhdk1?	MVvTRW5ITVJ?
EW-11	M{DWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPHV4NuUUN3ME25Ok45QCCwTR?=	NWHySIRzW0GQR1XS
GAK	M3Ltfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjmdphKSzVyPUm4Mlk{KG6P	NVHyUoJDW0GQR1XS
SK-OV-3	NHvYPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HYdGlEPTB;MUCwMlA4KG6P	MUTTRW5ITVJ?
OMC-1	M{PpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3O2eWlEPTB;MUCwMlE5KG6P	MVvTRW5ITVJ?
TK10	NXzIUZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfXTWM2OD1zMECuNlEhdk1?	M1\3PXNCVkeHUh?=
EKVX	NXPzT2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTFyMD62JI5O	Mlz1V2FPT0WU
Detroit562	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjiUIxKSzVyPUGwNk4yPyCwTR?=	NH3CRVBUSU6JRWK=
SF268	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC5NJNlUUN3ME2xNFIvOzRibl2=	NWj4flVTW0GQR1XS
SNU-387	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV6w[mI1UUN3ME2xNFQvOTdibl2=	NYnwXGxCW0GQR1XS
MDA-MB-231	MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnmTWM2OD1zMEWuNFYhdk1?	NF3VbIFUSU6JRWK=
NCI-H1563	NEmwe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPlTpJKSzVyPUGwOU4yQCCwTR?=	NGLHeVJUSU6JRWK=
D-502MG	MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjF[Hd{UUN3ME2xNFUvPyCwTR?=	NXXUXYJzW0GQR1XS
A2780	NWLTUJdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEn2d5pKSzVyPUGwOk41PyCwTR?=	MYPTRW5ITVJ?
IA-LM	M2TPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vwVWlEPTB;MUC3MlUyKG6P	NUHWbodZW0GQR1XS
D-392MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2G4O2lEPTB;MUC3MlU1KG6P	MYrTRW5ITVJ?
MS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFyNz63NUBvVQ>?	M3zUZnNCVkeHUh?=
SW1990	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnuPVIyUUN3ME2xNFgvPTRibl2=	M3;zRXNCVkeHUh?=
HEL	NUToSmFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFyOT6yPUBvVQ>?	MkDxV2FPT0WU
SW1573	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFyOT6zNUBvVQ>?	NHrtO4FUSU6JRWK=
SW1783	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXHSFZKSzVyPUGxNE4zOiCwTR?=	NGnMfW1USU6JRWK=
COLO-680N	NV34[WF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLUTWM2OD1zMUCuO\|Yhdk1?	M{\VfXNCVkeHUh?=
NCI-N87	M3XwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjL[GlGUUN3ME2xNVEvODRibl2=	NWLmTW5IW0GQR1XS
SK-MEL-28	M4nVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1v0VGlEPTB;MUGxMlU2KG6P	NH[5UoVUSU6JRWK=
BT-20	NF2ycWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\Te3BKSzVyPUGxNk4xOSCwTR?=	NWPrb21[W0GQR1XS
NCI-H1648	NVHmUJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDDTJROUUN3ME2xNVMhdk1?	MoLLV2FPT0WU
no-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37LUmlEPTB;MUGzMlI5KG6P	NX7PT4VVW0GQR1XS
MOLT-13	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor6TWM2OD1zMUOuOFQhdk1?	NGjKVmVUSU6JRWK=
NCI-H2170	NHTHWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PqN2lEPTB;MUG0MlUyKG6P	MWjTRW5ITVJ?
HTC-C3	NU\POnE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUj1cVNXUUN3ME2xNVYvQDVibl2=	MVjTRW5ITVJ?
LU-99A	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml31TWM2OD1zMUeuNlEhdk1?	MmPHV2FPT0WU
HCC2998	M3rCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF64eZhKSzVyPUGxO{46OiCwTR?=	NIXyNmZUSU6JRWK=
NB13	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\OfmlEPTB;MUG3Mlk6KG6P	NEDmN3dUSU6JRWK=
GT3TKB	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO1fVFKSzVyPUGxPE4xQCCwTR?=	NGD1ZW1USU6JRWK=
BT-549	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnLO2RKSzVyPUGxPE46PSCwTR?=	NVO3eIIyW0GQR1XS
NCI-H747	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1qx[WlEPTB;MUG5MlM1KG6P	NHOwTYhUSU6JRWK=
EW-1	M4DIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml61TWM2OD1zMkCuNkBvVQ>?	NXTu[GRZW0GQR1XS
LB831-BLC	NYXXT3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIe5dI1KSzVyPUGyNE43OyCwTR?=	NXnM[28xW0GQR1XS
NMC-G1	NV70R5cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH3OGdKUUN3ME2xNlEvOTFibl2=	MorwV2FPT0WU
COLO-679	NGPPb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnPdZNKSzVyPUGyNk4yPSCwTR?=	MoL6V2FPT0WU
HL-60	NWOyR29KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHKTWM2OD1zMkOuNUBvVQ>?	NHnLN\|ZUSU6JRWK=
MKN7	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTF{Mz64N{BvVQ>?	NHX2RlFUSU6JRWK=
RERF-LC-MS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHkTWM2OD1zMkSuN\|Ehdk1?	Moi0V2FPT0WU
DMS-114	M1T5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rjS2lEPTB;MUK1MlA6KG6P	NX7KNYtxW0GQR1XS
HuP-T4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PyO2lEPTB;MUK2Mlk4KG6P	M3fWWHNCVkeHUh?=
HCC2157	NX;xVXBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\S[o5KSzVyPUGyO{42KG6P	NIDmNVJUSU6JRWK=
SKG-IIIa	NEG1WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFiyfYZKSzVyPUGyPE45KG6P	NXnPenE1W0GQR1XS
HCT-116	NUjkeXd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHscVV2UUN3ME2xN\|AvPjRibl2=	MWTTRW5ITVJ?
BB30-HNC	NWjFWoN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfkb5hzUUN3ME2xN\|AvPzhibl2=	NHr6VoZUSU6JRWK=
KYSE-270	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37ORWlEPTB;MUOwMlg5KG6P	NYLqWGFMW0GQR1XS
MFM-223	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVq1TJJSUUN3ME2xN\|EvPTFibl2=	MnzlV2FPT0WU
NH-12	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\Z[plQUUN3ME2xN\|IvQTlibl2=	MoTvV2FPT0WU
U-118-MG	NFHlZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PYemlEPTB;MUOzMlYzKG6P	NH;sRVdUSU6JRWK=
ESS-1	M4\Wcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPqenRbUUN3ME2xN\|UvOThibl2=	M2PpNnNCVkeHUh?=
D-247MG	M2\N[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnsNZdsUUN3ME2xN\|UvOjFibl2=	NEHx[mJUSU6JRWK=
IGROV-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrnTWM2OD1zM{WuO\|Yhdk1?	MluwV2FPT0WU
C-33-A	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTF\|NT65O{BvVQ>?	NUjDTZlNW0GQR1XS
NCI-H1693	NUHMUpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\iWGlEPTB;MUO2MlEzKG6P	MYjTRW5ITVJ?
MLMA	NVzCS2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXzOFRKSzVyPUGzOk42QCCwTR?=	M3XIdHNCVkeHUh?=
SK-N-AS	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTF\|Nz6xO{BvVQ>?	Mn60V2FPT0WU
NCI-H1755	NIDYUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTF\|OD64OUBvVQ>?	NF7ZVJFUSU6JRWK=
CHP-134	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7sW4VsUUN3ME2xN\|kvPTVibl2=	NUTxb25ZW0GQR1XS
LS-513	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfwU\|VKSzVyPUG0NE46OSCyTR?=	NH65WJlUSU6JRWK=
TE-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTTZWdUUUN3ME2xOFAvQTNibl2=	MkTnV2FPT0WU
KNS-42	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTF2ND6zJI5O	M3S4cHNCVkeHUh?=
SJRH30	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjwSnhqUUN3ME2xOFQvPDRibl2=	MnHuV2FPT0WU
NCI-H1092	NYfZVFAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITHWINKSzVyPUG0OE42OiCwTR?=	M1:4THNCVkeHUh?=
H-EMC-SS	NXW0cY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF2Nj64NUBvVQ>?	MWrTRW5ITVJ?
SK-MEL-3	M2nEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LUZmlEPTB;MUS3MlU2KG6P	NETnUnFUSU6JRWK=
SK-N-FI	M1i4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTF2Nz61PUBvVQ>?	M3rhTXNCVkeHUh?=
NCI-H2126	NH3oPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnjTWM2OD1zNEiuNVUhdk1?	NFvGOFZUSU6JRWK=
NCI-H1299	NV\JVm9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTF3MD6yNkBvVQ>?	NEfYT\|RUSU6JRWK=
CFPAC-1	NH;C[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LSWWlEPTB;MUWwMlY3KG6P	NEHsVGZUSU6JRWK=
NCI-H661	Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3RdmdKSzVyPUG1NU4zPiCwTR?=	MkjRV2FPT0WU
KYSE-70	M1;le2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFn2PW1KSzVyPUG1NU44QSCwTR?=	MV;TRW5ITVJ?
SW900	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlL0TWM2OD1zNUSuOlUhdk1?	MnrtV2FPT0WU
Ca-Ski	M{[1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHsTWM2OD1zNU[uN\|khdk1?	NWDqRpJKW0GQR1XS
HPAF-II	M2TRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF3Nj60O{BvVQ>?	MkjDV2FPT0WU
LB2518-MEL	NHHDfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHmxcYZKSzVyPUG1O{4yKG6P	M{jtWXNCVkeHUh?=
LC-2-ad	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPGbIRKSzVyPUG1PE43OiCwTR?=	NX7aPFNKW0GQR1XS
HCC1806	NYXxUXg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTF4Nz64PEBvVQ>?	M4jFfnNCVkeHUh?=
UACC-62	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIP6cHpKSzVyPUG2PE4xQSCwTR?=	MU\TRW5ITVJ?
KM-H2	NEfF[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:xVXZKSzVyPUG3NE42QCCwTR?=	NH;3OJhUSU6JRWK=
NCI-H2347	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFX2NpBKSzVyPUG3Nk44OiCwTR?=	NIOzVnpUSU6JRWK=
SCC-15	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nEdWlEPTB;MUezMlY3KG6P	MWPTRW5ITVJ?
BB49-HNC	NYH1OlRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O5NmlEPTB;MUezMlgyKG6P	NYC3c2tvW0GQR1XS
GMS-10	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLCW29KSzVyPUG3N{46PCCwTR?=	NVTrU4VNW0GQR1XS
NCI-H2052	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF5ND65JI5O	MVTTRW5ITVJ?
SW626	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnhdnRKSzVyPUG3Ok4xPiCwTR?=	NYq1eWE1W0GQR1XS
MDA-MB-415	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fEdmlEPTB;MUe2MlYyKG6P	NWHBZVVxW0GQR1XS
Saos-2	NXfXXnFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTF5OT6zOUBvVQ>?	MWjTRW5ITVJ?
DK-MG	NYrT[4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrOPHJKSzVyPUG4NE4{KG6P	MlXNV2FPT0WU
SNU-C2B	M{DEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFv4Z\|JKSzVyPUG4NE44OyCwTR?=	M4PPXXNCVkeHUh?=
A427	M1PSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTlcHV2UUN3ME2xPFIvPTdibl2=	NIKwR2dUSU6JRWK=
KP-N-YS	NWrSUJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTF6NTDuUS=>	M4HmVnNCVkeHUh?=
J82	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPmV4dKSzVyPUG4OU4yQCCwTR?=	MV3TRW5ITVJ?
LS-411N	M2X3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rJW2lEPTB;MUi3MlI5KG6P	M3GxNnNCVkeHUh?=
HCC1937	NHf1e5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTF6Nz60PUBvVQ>?	NFHlRlBUSU6JRWK=
OE33	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjRXXRKSzVyPUG4PE46PyCwTR?=	Mn\XV2FPT0WU
NB7	M3m3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF6OT64PUBvVQ>?	NYPwV2VEW0GQR1XS
SW684	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17Vb2lEPTB;MUm2MlE{KG6P	NF3IUnNUSU6JRWK=
HT-144	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnITWM2OD1zOU[uNVUhdk1?	NHnqNZZUSU6JRWK=
SK-MEL-30	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTF7Nj6yJI5O	NVGye5RCW0GQR1XS
DBTRG-05MG	NXTU[IJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XLfmlEPTB;MUm4MlQ4KG6P	NXPmXFhiW0GQR1XS
NCI-H1395	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXmTWM2OD1zOUiuPFUhdk1?	NVPzWFZlW0GQR1XS
NCI-H2122	M2fH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moe2TWM2OD1{MECuOVkhdk1?	NVjWT\|lIW0GQR1XS
no-10	NHTqfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHibolKSzVyPUKwNU4xPCCwTR?=	M4GzO3NCVkeHUh?=
SW48	NX:w[3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3MeFlKSzVyPUKwNU4{OSCwTR?=	MWXTRW5ITVJ?
NCI-H1650	NIGxfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjNR5FOUUN3ME2yNFQvODFibl2=	NFj4eXdUSU6JRWK=
MZ1-PC	NYPHT2h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTJyNT61PEBvVQ>?	Ml7PV2FPT0WU
U-266	NYezNIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LRZmlEPTB;MkC1Mlc6KG6P	M37SNHNCVkeHUh?=
CAS-1	M4T6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUD3[pl3UUN3ME2yNFcvPDRibl2=	MVjTRW5ITVJ?
AU565	NFLtWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3GxPGlEPTB;MkGyMlgzKG6P	M332cXNCVkeHUh?=
UACC-257	M1PvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r0TmlEPTB;MkGzMlk6KG6P	NHLMeYFUSU6JRWK=
CAL-27	M4LlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jOWWlEPTB;MkG3MlA2KG6P	M17GTnNCVkeHUh?=
NCI-H23	M2rGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzScpVKSzVyPUKxPU4{OyCwTR?=	MUDTRW5ITVJ?
TE-6	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPyfoZKSzVyPUKxPU43QCCwTR?=	NHzmRoFUSU6JRWK=
TGBC24TKB	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ{Mj6xO{BvVQ>?	MljJV2FPT0WU
TE-1	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPlcGxKSzVyPUKyNk45QCCwTR?=	NV;IfJVFW0GQR1XS
RCC10RGB	M17OZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTrTWM2OD1{MkSuNVkhdk1?	MW\TRW5ITVJ?
NCI-H596	M1zkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DtVGlEPTB;MkK4MlIzKG6P	NFfL[5FUSU6JRWK=
SW954	NUHyZXZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorGTWM2OD1{M{OuPFMhdk1?	NVn4O3BFW0GQR1XS
NCI-H2087	MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJ\|ND61NUBvVQ>?	M33jeXNCVkeHUh?=
SK-PN-DW	NF[4[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTQVZFKSzVyPUKzOU4yQSCwTR?=	M{i1ZXNCVkeHUh?=
KM12	M1nQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfPTWdoUUN3ME2yN\|UvPyCwTR?=	NXL0SlBEW0GQR1XS
BT-474	M3zkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\JTWM2OD1{M{WuO\|Mhdk1?	MknMV2FPT0WU
IST-MES1	NGnxPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7LcGdKSzVyPUKzOk42PyCwTR?=	M3zPZXNCVkeHUh?=
HT-1197	NISyW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PhTGlEPTB;MkO4MlA6KG6P	MX7TRW5ITVJ?
CAL-54	NX\lT4luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUSxb4VVUUN3ME2yN\|gvPDlibl2=	NIX6dGhUSU6JRWK=
NB10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXKyR5lLUUN3ME2yOFAvODZibl2=	Mm\uV2FPT0WU
PANC-10-05	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrsXm5EUUN3ME2yOFUvPTZibl2=	M4fnXXNCVkeHUh?=
NCI-H522	NIrjTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnJPGdVUUN3ME2yOFgvOzFibl2=	NGPjOnJUSU6JRWK=
A388	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TJNmlEPTB;MkS5MlgzKG6P	MlPGV2FPT0WU
GOTO	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jhZmlEPTB;MkWwMlI6KG6P	NHfyZ21USU6JRWK=
KLE	NVXPW5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJ3MT64O{BvVQ>?	MmS1V2FPT0WU
KYSE-520	M{m2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHnTWM2OD1{NUKuPFYhdk1?	M4PkcHNCVkeHUh?=
HCE-4	NVrie3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\yTWM2OD1{NkKuOUBvVQ>?	MoDBV2FPT0WU
KURAMOCHI	NXPkXIxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LPbGlEPTB;Mk[1Mlkhdk1?	M1fDSHNCVkeHUh?=
HCC38	NG\a[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TCOmlEPTB;Mk[2MlQ5KG6P	NW\JZpdQW0GQR1XS
FADU	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjXTHRwUUN3ME2yOlYvPjNibl2=	MkPkV2FPT0WU
CW-2	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnwWlVKSzVyPUK2PU46PiCwTR?=	NYjuflFLW0GQR1XS
L-428	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrwc2ljUUN3ME2yO\|UvOTVibl2=	NYnl[G9PW0GQR1XS
HCC1569	NWT6N2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H6O2lEPTB;Mke1Mlg1KG6P	NEDMVlBUSU6JRWK=
NCI-H810	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LSU2lEPTB;Mke4MlMyKG6P	NW[y[4pRW0GQR1XS
LB771-HNC	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjwUZFKSzVyPUK4OU45PCCwTR?=	M4G4NXNCVkeHUh?=
LCLC-103H	NUfKWmExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3DTWM2OD1{OEWuPVkhdk1?	NUT5NWVDW0GQR1XS
EFO-21	M1rsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\wTWM2OD1{OEeuOlghdk1?	NW\uc5NzW0GQR1XS
CAL-72	NX3iUoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nwe2lEPTB;MkmzMlE6KG6P	MknVV2FPT0WU
SCC-9	NFjGWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJ7Mz6yNkBvVQ>?	MYXTRW5ITVJ?
COLO-829	M37ESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjWUnExUUN3ME2yPVYvPSCwTR?=	MmfUV2FPT0WU
U-87-MG	M2XhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHBTWM2OD1\|MECuO\|Mhdk1?	M{LZWXNCVkeHUh?=
MZ7-mel	M4LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\HUmlEPTB;M{KzMlc3KG6P	M2eycXNCVkeHUh?=
NCI-H1770	NYXEOGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTN{Nj63OEBvVQ>?	NYHhVHJVW0GQR1XS
ChaGo-K-1	M{XVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TaeWlEPTB;M{K4MlEhdk1?	MVTTRW5ITVJ?
SiHa	M3zG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTN{OT6yOEBvVQ>?	MnXIV2FPT0WU
NCI-SNU-5	NHLVd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHQe21KSzVyPUOzOk44PyCwTR?=	M{Pid3NCVkeHUh?=
DJM-1	M{TkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rPOmlEPTB;M{SwMlM{KG6P	NETHOoZUSU6JRWK=
OE19	NHzWcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTN2MD61N{BvVQ>?	MWLTRW5ITVJ?
NCI-H1651	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnC[\|BKSzVyPUO0OE4yQCCwTR?=	M4\2eXNCVkeHUh?=
COLO-792	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTN3ND60NkBvVQ>?	NVPzbYdMW0GQR1XS
ACHN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;wV2lEPTB;M{W2MlcyKG6P	MVnTRW5ITVJ?
TH-3	M2fsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGj5bYxKSzVyPUO3PU46PSCwTR?=	M3;0Z3NCVkeHUh?=
HT-1376	NVHPTmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1GwPWlEPTB;M{i0Mlg5KG6P	NUf6dIl{W0GQR1XS
RH-18	NXnaSZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzt[4d4UUN3ME2zPVQvPzRibl2=	Mnm5V2FPT0WU
NB6	M37odGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHWSYVKSzVyPUO5Ok43PiCwTR?=	MmXFV2FPT0WU
COLO-320-HSR	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTRyMz6zO{BvVQ>?	M1fmbnNCVkeHUh?=
UACC-893	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1f6WGlEPTB;NEC2MlQ4KG6P	NGrU[llUSU6JRWK=
DSH1	M1\acmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfpTWM2OD12ME[uPVEhdk1?	M3XQUnNCVkeHUh?=
TE-10	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH6TWM2OD12MEeuNFEhdk1?	NELIV5hUSU6JRWK=
HCC70	NFjpOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPGc5BKUUN3ME20NFkvOjFibl2=	MojFV2FPT0WU
TGBC11TKB	M3jUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljWTWM2OD12MUCuN\|Mhdk1?	MVPTRW5ITVJ?
NCI-H727	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3ISldKSzVyPUSxNk4yOSCwTR?=	MXTTRW5ITVJ?
ALL-PO	M13Cfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mln6TWM2OD12MUWuOlkhdk1?	NUDS[mZ2W0GQR1XS
ABC-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nVWWlEPTB;NEKwMlQ2KG6P	MmjmV2FPT0WU
NCI-H69	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nkWmlEPTB;NEK2Mlc3KG6P	NYG4eoVMW0GQR1XS
GP5d	M33MU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWKzNHFIUUN3ME20N\|QvPDFibl2=	NV3FdmtvW0GQR1XS
UMC-11	M{XlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTR3OD6zOkBvVQ>?	NWHjT5dWW0GQR1XS
RMG-I	M1PKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXLe\|RiUUN3ME20OlcvPTZibl2=	Ml;0V2FPT0WU
YAPC	NXfjNGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTR7MD62JI5O	NVWxVIFGW0GQR1XS
LS-1034	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Tn[mlEPTB;NEmxMlA3KG6P	NYTEfZVJW0GQR1XS
RCM-1	NHTlR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTR7Nj62PEBvVQ>?	MUHTRW5ITVJ?
HCC1954	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvs[ZdbUUN3ME21NVIvPSCwTR?=	NWK5OGNqW0GQR1XS
SK-MEL-24	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTVzNj61NUBvVQ>?	MV7TRW5ITVJ?
NB12	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7YTWM2OD13MkiuOFIhdk1?	NYXhPGNXW0GQR1XS
SW756	NIX2fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rLXWlEPTB;NUW0Mlk3KG6P	MmH4V2FPT0WU
HCC1187	M{jwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTV5NT64N{BvVQ>?	M2PVVXNCVkeHUh?=
NCI-H2342	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnIcYhzUUN3ME21PVAvOzlibl2=	MnHpV2FPT0WU
NCI-H2291	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfLTWM2OD13OUiuN\|Ehdk1?	MlGxV2FPT0WU
OVCAR-3	NUfTVVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTV7OD65OkBvVQ>?	MknGV2FPT0WU
MHH-NB-11	M2fOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHWTWM2OD14MkmuNFEhdk1?	NHrOSIpUSU6JRWK=
SAS	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rufmlEPTB;NkWyMlY4KG6P	Mn61V2FPT0WU
COLO-824	NYnuSI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz5TWM2OD14OEmuN\|chdk1?	NIPXZYxUSU6JRWK=
HCC1395	NH\wO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XrOWlEPTB;Nkm4MlUhdk1?	MXHTRW5ITVJ?
COLO-668	NHzoc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;oWopKSzVyPUewOk4yKG6P	NWP2[HFuW0GQR1XS
NCI-H226	NFrkPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfmZ4lkUUN3ME23NFcvQCCwTR?=	MofvV2FPT0WU
NB17	NWP1OVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7MTWM2OD15MkGuO\|Uhdk1?	Mlz2V2FPT0WU
SW1463	NH;4c\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTd\|OT6xPUBvVQ>?	NE\xOJNUSU6JRWK=
TGW	NFT5NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTd4MD6xOUBvVQ>?	MYfTRW5ITVJ?
NCI-H526	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTh{Mz61N{BvVQ>?	M4jZUnNCVkeHUh?=
COR-L88	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rtUmlEPTB;OES4MlEzKG6P	MUDTRW5ITVJ?
NCI-H441	NED2W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfxWI5wUUN3ME24PVUvOjJibl2=	MXzTRW5ITVJ?
NCI-H630	MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHuTWM2OD17MUKuPVYhdk1?	M133d3NCVkeHUh?=
Mo-T	NU\ye3BQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPOfppKSzVyPUm0O{45QCCwTR?=	MVnTRW5ITVJ?
JAR	NULMOoFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHKTIlKSzVyPUm1Ok4zPCCwTR?=	M2KwXXNCVkeHUh?=
NCI-H1838	NIfSSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET2OW5KSzVyPUGuNFI{QDhizszN	NGXMb5FUSU6JRWK=
DoTc2-4510	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonXTWM2OD1zLkC3N\|c3KM7:TR?=	MU\TRW5ITVJ?
MKN28	NFnaNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr3UVBKSzVyPUGuNFkxOjRizszN	M1TCO3NCVkeHUh?=
HuP-T3	M{HKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjVU4VOUUN3ME2xMlEyQTB3IN88US=>	NWWwWWR1W0GQR1XS
TE-9	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTFwMUK5O\|Mh\|ryP	MkfKV2FPT0WU
NY	NED6U2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnntTWM2OD1zLkG2O\|kzKM7:TR?=	M1SzV3NCVkeHUh?=
HT55	M{\0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TuN2lEPTB;MT6zNVM1PCEQvF2=	M2rZd3NCVkeHUh?=
SW837	NXuwTpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:1NWVwUUN3ME2xMlMzQTd6IN88US=>	MXnTRW5ITVJ?
NCI-H2029	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjufVFKSzVyPUGuOFE4QTFizszN	M2K1U3NCVkeHUh?=
IST-SL1	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLrTpprUUN3ME2xMlQ1OjRizszN	NYfzXVRXW0GQR1XS
COLO-741	NEOwco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjQSWRKSzVyPUGuOFk4PzFizszN	M1jNZnNCVkeHUh?=
LU-65	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{W4TmlEPTB;MT62NlI1QSEQvF2=	MW\TRW5ITVJ?
NCI-H1304	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlH0TWM2OD1zLk[1OFk5KM7:TR?=	MoPxV2FPT0WU
KARPAS-299	NITEfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFwN{m0O\|kh\|ryP	M36zRXNCVkeHUh?=
NCI-H358	M1:1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGL1SoFKSzVyPUGuPVU2ODNizszN	MV7TRW5ITVJ?
OAW-28	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHIT3VUUUN3ME2yMlA3QTF7IN88US=>	M{jzeXNCVkeHUh?=
C8166	M2ft[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTFdFdNUUN3ME2yMlY{Ozl{IN88US=>	NHGyS4dUSU6JRWK=
COLO-678	M4H2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwOEO3Olgh\|ryP	NF\yUZRUSU6JRWK=
SK-N-DZ	M363[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fNemlEPTB;Mj64OlM5OSEQvF2=	M3\4Z3NCVkeHUh?=
NCI-H82	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVe1NWJYUUN3ME2yMlkxOzZ7IN88US=>	M1fEcnNCVkeHUh?=
JVM-2	M3zJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTNwMEOxPFgh\|ryP	NG[wUppUSU6JRWK=
SW1116	M1rtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTNwMEW0NVEh\|ryP	MXTTRW5ITVJ?
MDA-MB-453	NWqz[pZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDXTWM2OD1\|LkGwOFM6KM7:TR?=	M2\2UXNCVkeHUh?=
Calu-6	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;tTWM2OD1\|LkG5PVch\|ryP	MlTWV2FPT0WU
SHP-77	NWDHfVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTNwNUK4JO69VQ>?	MV3TRW5ITVJ?
Capan-2	M4rW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVznfZJEUUN3ME20MlMzPThzIN88US=>	M1jzWHNCVkeHUh?=
SW948	M1XyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXOd5VKSzVyPUSuO\|Q4PzlizszN	NY\STIFrW0GQR1XS
HDLM-2	M3XSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nkVWlEPTB;NT6wO\|czPSEQvF2=	MnfKV2FPT0WU
LAN-6	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTJZlFoUUN3ME22MlIyPDl3IN88US=>	MlKwV2FPT0WU
LU-135	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\XenJKSzVyPU[uOFMxPzdizszN	M4\4d3NCVkeHUh?=
T84	NIq4[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnO2TWM2OD14Lkm4OlQh\|ryP	MYXTRW5ITVJ?
CAPAN-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrhU3R5UUN3ME23MlYzOjN\|IN88US=>	M4TmSnNCVkeHUh?=
SW1417	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjQTWM2OD15LkmxO\|MyKM7:TR?=	NYCyNJo6W0GQR1XS
BALL-1	NF:zNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjMfFJLUUN3ME24MlUxPDB7IN88US=>	MnjlV2FPT0WU
HT-29	NXXicmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fnWmlEPTB;OT6wO\|U6QSEQvF2=	MV\TRW5ITVJ?
C3A	NXrid2djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXrNoFKSzVyPUmuPFg{QTRizszN	MWfTRW5ITVJ?
NCI-H1993	M4T4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnUZ\|NpUUN3ME2xNE42ODhzIN88US=>	NWe1cHZtW0GQR1XS
SK-MEL-1	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL0fFc{UUN3ME2xNU43Ojh7IN88US=>	NFm4c4xUSU6JRWK=
DU-145	M2fmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;ITWM2OD1zND61NFUzKM7:TR?=	NVvnPZJYW0GQR1XS
KP-N-YN	NHr6OVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETtV5ZKSzVyPUG0MlUyODNizszN	NY\SWpVPW0GQR1XS
CCRF-CEM	M37VXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHvTpRKSzVyPUG0Mlc5ODlizszN	M2jibHNCVkeHUh?=
ZR-75-30	NUHLZ5pKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfsTWM2OD1zNj6zN\|A{KM7:TR?=	M1r5UXNCVkeHUh?=
A673	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnS4TWM2OD1{MD61OVA4KM7:TR?=	M1:1WHNCVkeHUh?=
K-562	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHx[YI5UUN3ME2yPE41OTh\|IN88US=>	NFLHZWpUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	+ Expand Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01482156	Completed	Drug: RAD001 + BEZ235	Advanced Solid Tumors\|Metastatic Breast Cancer\|Metastatic Renal Cell Carcinoma	Novartis Pharmaceuticals\|Novartis	January 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 203 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 203 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)